Cancer Causes & Control

, Volume 24, Issue 8, pp 1465–1480 | Cite as

Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research

Review article
  • 273 Downloads

Abstract

Prostate cancer is the most frequently diagnosed malignancy in men. However, African American/Black men are 60 % more likely to be diagnosed with and 2.4 times more likely to die from prostate cancer, compared to Non-Hispanic White men. Despite the increased burden of this malignancy, no evidence-based recommendation regarding prostate cancer screening exists for the high-risk population. Moreover, in addition to screening and detection, African American men may constitute a prime population for chemoprevention. Early detection and chemoprevention may thus represent an integral part of prostate cancer control in this population. Importantly, recent research has elucidated biological differences in the prostate tumors of African American compared to European American men. The latter may enable a more favorable response in African American men to specific chemopreventive agents that target relevant signal transduction pathways. Based on this evolving evidence, the aims of this review are threefold. First, we aim to summarize the biological differences that were reported in the prostate tumors of African American and European American men. Second, we will review the single- and multi-target chemopreventive agents placing specific emphasis on the pathways implicated in prostate carcinogenesis. And lastly, we will discuss the most promising nutraceutical chemopreventive compounds. Our review underscores the promise of chemoprevention in prostate cancer control, as well as provides justification for further investment in this filed to ultimately reduce prostate cancer morbidity and mortality in this high-risk population of African American men.

Keywords

Prostate cancer African American/Black men Evidence-based chemoprevention Pharmaceutical compounds Nutraceutical compounds 

References

  1. 1.
    Cancer Facts & Figures for African Americans 2011–2012 (2011). American Cancer SocietyGoogle Scholar
  2. 2.
    Cancer Facts & Figures 2012 (2012). American Cancer SocietyGoogle Scholar
  3. 3.
    Chornokur G, Dalton K, Borysova ME, Kumar NB (2011) Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer. Prostate 71(9):985–997. doi:10.1002/pros.21314 PubMedCrossRefGoogle Scholar
  4. 4.
    Powell IJ (2007) Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 177(2):444–449. doi:10.1016/j.juro.2006.09.024 PubMedCrossRefGoogle Scholar
  5. 5.
    Ilic D, O’Connor D, Green S, Wilt TJ (2011) Screening for prostate cancer: an updated Cochrane systematic review. BJU Int 107(6):882–891. doi:10.1111/j.1464-410X.2010.10032.x PubMedCrossRefGoogle Scholar
  6. 6.
    Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319. doi:10.1056/NEJMoa0810696 PubMedCrossRefGoogle Scholar
  7. 7.
    Moyer VA (2012) Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 157(2):120–134. doi:10.7326/0003-4819-157-2-201207170-00459 PubMedCrossRefGoogle Scholar
  8. 8.
    Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J, Ciatto S, Kwiatkowski M, Villers A, Lujan M, Nelen V, Tammela TL, Schroder FH (2010) The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer 126(10):2387–2393. doi:10.1002/ijc.24870 PubMedGoogle Scholar
  9. 9.
    Shuch B, Mikhail M, Satagopan J, Lee P, Yee H, Chang C, Cordon-Cardo C, Taneja SS, Osman I (2004) Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol 22(23):4725–4729. doi:10.1200/JCO.2004.06.134 PubMedCrossRefGoogle Scholar
  10. 10.
    Ladanyi M, Pao W (2008) Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21(Suppl 2):S16–S22. doi:10.1038/modpathol.3801018 PubMedCrossRefGoogle Scholar
  11. 11.
    Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL (2009) Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28(43):3801–3813. doi:10.1038/onc.2009.234 PubMedCrossRefGoogle Scholar
  12. 12.
    Gaston KE, Kim D, Singh S, Ford OH 3rd, Mohler JL (2003) Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. J Urol 170(3):990–993. doi:10.1097/01.ju.0000079761.56154.e5 PubMedCrossRefGoogle Scholar
  13. 13.
    Kim HS, Moreira DM, Jayachandran J, Gerber L, Banez LL, Vollmer RT, Lark AL, Donovan MJ, Powell D, Khan FM, Freedland SJ (2011) Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. Prostate Cancer Prostatic Dis 14(3):262–265. doi:10.1038/pcan.2011.18 PubMedCrossRefGoogle Scholar
  14. 14.
    Olapade-Olaopa EO, Muronda CA, MacKay EH, Danso AP, Sandhu DP, Terry TR, Habib FK (2004) Androgen receptor protein expression in prostatic tissues in Black and Caucasian men. Prostate 59(4):460–468. doi:10.1002/pros.20014 PubMedCrossRefGoogle Scholar
  15. 15.
    Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20(13):3001–3015PubMedCrossRefGoogle Scholar
  16. 16.
    Lattouf JB, Srinivasan R, Pinto PA, Linehan WM, Neckers L (2006) Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat Clin Pract Urol 3(11):590–601. doi:10.1038/ncpuro0604 PubMedCrossRefGoogle Scholar
  17. 17.
    Sarkar FH, Li Y, Wang Z, Kong D (2010) Novel targets for prostate cancer chemoprevention. Endocr Relat Cancer 17(3):R195–R212. doi:10.1677/ERC-10-0074 PubMedCrossRefGoogle Scholar
  18. 18.
    Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61(7):2892–2898PubMedGoogle Scholar
  19. 19.
    Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, Yager JD, Platz EA (2007) Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. J Clin Endocrinol Metab 92(7):2519–2525. doi:10.1210/jc.2007-0028 PubMedCrossRefGoogle Scholar
  20. 20.
    Litman HJ, Bhasin S, Link CL, Araujo AB, McKinlay JB (2006) Serum androgen levels in black, Hispanic, and white men. J Clin Endocrinol Metab 91(11):4326–4334. doi:10.1210/jc.2006-0037 PubMedCrossRefGoogle Scholar
  21. 21.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013 PubMedCrossRefGoogle Scholar
  22. 22.
    deVere White RW, Deitch AD, Jackson AG, Gandour-Edwards R, Marshalleck J, Soares SE, Toscano SN, Lunetta JM, Stewart SL (1998) Racial differences in clinically localized prostate cancers of black and white men. J Urol 159(6):1979–1982; discussion 1982–1973PubMedCrossRefGoogle Scholar
  23. 23.
    Guo Y, Sigman DB, Borkowski A, Kyprianou N (2000) Racial differences in prostate cancer growth: apoptosis and cell proliferation in Caucasian and African-American patients. Prostate 42(2):130–136PubMedCrossRefGoogle Scholar
  24. 24.
    Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, Stephens RM, Caporaso NE, Loffredo CA, Ambs S (2008) Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 68(3):927–936. doi:10.1158/0008-5472.CAN-07-2608 PubMedCrossRefGoogle Scholar
  25. 25.
    Jiang WG, Raz A, Douglas-Jones A, Mansel RE (2006) Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. J Histochem Cytochem 54(2):231–241. doi:10.1369/jhc.5A6785.2005 PubMedCrossRefGoogle Scholar
  26. 26.
    Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62(6):1832–1837PubMedGoogle Scholar
  27. 27.
    Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA (2007) Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 11(6):526–538. doi:10.1016/j.ccr.2007.04.020 PubMedCrossRefGoogle Scholar
  28. 28.
    Heresi GA, Wang J, Taichman R, Chirinos JA, Regalado JJ, Lichtstein DM, Rosenblatt JD (2005) Expression of the chemokine receptor CCR7 in prostate cancer presenting with generalized lymphadenopathy: report of a case, review of the literature, and analysis of chemokine receptor expression. Urol Oncol 23(4):261–267. doi:10.1016/j.urolonc.2005.02.004 PubMedCrossRefGoogle Scholar
  29. 29.
    London CA, Sekhon HS, Arora V, Stein DA, Iversen PL, Devi GR (2003) A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 10(11):823–832. doi:10.1038/sj.cgt.7700642 PubMedCrossRefGoogle Scholar
  30. 30.
    Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182(3):311–322. doi:10.1002/(SICI)1097-4652(200003)182:3<311:AID-JCP1>3.0.CO;2-9 PubMedCrossRefGoogle Scholar
  31. 31.
    Yang G, Addai J, Ittmann M, Wheeler TM, Thompson TC (2000) Elevated caveolin-1 levels in African-American versus white-American prostate cancer. Clin Cancer Res 6(9):3430–3433PubMedGoogle Scholar
  32. 32.
    Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, Bohm D, Perner S, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S (2012) Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 80(4):749–753. doi:10.1016/j.urology.2012.07.001 PubMedCrossRefGoogle Scholar
  33. 33.
    Reams RR, Agrawal D, Davis MB, Yoder S, Odedina FT, Kumar N, Higginbotham JM, Akinremi T, Suther S, Soliman KF (2009) Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. Infect Agent Cancer 4(Suppl 1):S3. doi:10.1186/1750-9378-4-S1-S3 PubMedCrossRefGoogle Scholar
  34. 34.
    Chien J, Staub J, Avula R, Zhang H, Liu W, Hartmann LC, Kaufmann SH, Smith DI, Shridhar V (2005) Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 24(32):5089–5100. doi:10.1038/sj.onc.1208700 PubMedCrossRefGoogle Scholar
  35. 35.
    Singh RP, Agarwal R (2006) Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 13(3):751–778. doi:10.1677/erc.1.01126 PubMedCrossRefGoogle Scholar
  36. 36.
    Walsh PC (2010) Chemoprevention of prostate cancer. N Engl J Med 362(13):1237–1238. doi:10.1056/NEJMe1001045 PubMedCrossRefGoogle Scholar
  37. 37.
    Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M (2010) An overview on 5 alpha-reductase inhibitors. Steroids 75(2):109–153. doi:10.1016/j.steroids.2009.10.005 PubMedCrossRefGoogle Scholar
  38. 38.
    Rittmaster RS (2008) 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Best Pract Res Clin Endocrinol Metab 22(2):389–402. doi:10.1016/j.beem.2008.01.016 PubMedCrossRefGoogle Scholar
  39. 39.
    Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS (2008) Five-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev (2):CD007091. doi:10.1002/14651858.CD007091
  40. 40.
    Theoret MR, Ning YM, Zhang JJ, Justice R, Keegan P, Pazdur R (2011) The risks and benefits of 5alpha-reductase inhibitors for prostate-cancer prevention. N Engl J Med 365(2):97–99. doi:10.1056/NEJMp1106783 PubMedCrossRefGoogle Scholar
  41. 41.
    Hong SK, Oh JJ, Lee S et al (2012) Association of 5a-reductase inhibitor use and pathological features of prostate cancer in men undergoing radical prostatectomy. Prostate 72(1187–1192):1187–1192PubMedCrossRefGoogle Scholar
  42. 42.
    Kramer BS, Hagerty KL, Justman S et al (2009) Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: american society of clinical oncology/American urological association 2008 clinical practice guideline. J Clin Oncol 27(9):1502–1516PubMedCrossRefGoogle Scholar
  43. 43.
    Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML (2011) Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 8(3):872–884. doi:10.1111/j.1743-6109.2010.02157.x PubMedCrossRefGoogle Scholar
  44. 44.
    5-alpha reductase inhibitor (5-ARSs) may increase the risk of a more serious form of prostate cancer. FDA Drug Safety Communication. http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm
  45. 45.
    Roehrborn CG, Ray P (2006) Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men. Prostate Cancer Prostatic Dis 9(4):432–438. doi:10.1038/sj.pcan.4500911 PubMedCrossRefGoogle Scholar
  46. 46.
    Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (1):CD004816. doi:10.1002/14651858.CD004816.pub4
  47. 47.
    Farwell WR, D’Avolio LW, Scranton RE, Lawler EV, Gaziano JM (2011) Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst 103(11):885–892. doi:10.1093/jnci/djr108 PubMedCrossRefGoogle Scholar
  48. 48.
    Brown M, Hart C, Tawadros T, Ramani V, Sangar V, Lau M, Clarke N (2012) The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer 106(10):1689–1696. doi:10.1038/bjc.2012.138 PubMedCrossRefGoogle Scholar
  49. 49.
    Silva MA, Swanson AC, Gandhi PJ, Tataronis GR (2006) Statin-related adverse events: a meta-analysis. Clin Ther 28(1):26–35. doi:10.1016/j.clinthera.2006.01.005 PubMedCrossRefGoogle Scholar
  50. 50.
    Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D (2005) Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev (3):CD002966. doi:10.1002/14651858.CD002966.pub3
  51. 51.
    Lord JM, Flight IH, Norman RJ (2003) Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 327(7421):951–953. doi:10.1136/bmj.327.7421.951 PubMedCrossRefGoogle Scholar
  52. 52.
    Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA (2010) Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9(6):1057–1064PubMedCrossRefGoogle Scholar
  53. 53.
    Clements A, Gao B, Yeap SH, Wong MK, Ali SS, Gurney H (2011) Metformin in prostate cancer: two for the price of one. Ann Oncol 22(12):2556–2560. doi:10.1093/annonc/mdr037 PubMedCrossRefGoogle Scholar
  54. 54.
    Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, Pasanisi P, Pilotti S (2012) Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene. doi:10.1038/onc.2012.181 PubMedGoogle Scholar
  55. 55.
    Wright JL, Stanford JL (2009) Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 20(9):1617–1622. doi:10.1007/s10552-009-9407-y PubMedCrossRefGoogle Scholar
  56. 56.
    Azoulay L, Dell’Aniello S, Gagnon B, Pollak M, Suissa S (2011) Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20(2):337–344. doi:10.1158/1055-9965.EPI-10-0940 PubMedCrossRefGoogle Scholar
  57. 57.
    Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147(6):386–399PubMedCrossRefGoogle Scholar
  58. 58.
    Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2003) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 163(21):2594–2602. doi:10.1001/archinte.163.21.2594 PubMedCrossRefGoogle Scholar
  59. 59.
    Nelson JE, Harris RE (2000) Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7(1):169–170PubMedGoogle Scholar
  60. 60.
    Harris RE, Beebe-Donk J, Doss H, Burr Doss D (2005) Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13(4):559–583PubMedGoogle Scholar
  61. 61.
    Mahmud S, Franco E, Aprikian A (2004) Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90(1):93–99. doi:10.1038/sj.bjc.6601416 PubMedCrossRefGoogle Scholar
  62. 62.
    Mahmud SM, Franco EL, Aprikian AG (2010) Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis Int. J. Cancer 127:1680–1691Google Scholar
  63. 63.
    Jafari S, Etminan M, Afshar K (2009) Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis. Can Urol Assoc J. 3(4):323–330PubMedGoogle Scholar
  64. 64.
    Habel LA, Zhao W, Stanford JL (2002) Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 13(5):427–434. doi:10.1023/A:1015788502099 PubMedCrossRefGoogle Scholar
  65. 65.
    Garcia Rodriguez LA, Gonzalez-Perez A (2004) Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 13(4):649–653PubMedGoogle Scholar
  66. 66.
    Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ (2005) A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 97(13):975–980. doi:10.1093/jnci/dji173 PubMedCrossRefGoogle Scholar
  67. 67.
    Basler JW, Piazza GA (2004) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. J Urol 171 (2 Pt 2):S59–S62; discussion S62–S53. doi:10.1097/01.ju.0000107839.06670.27
  68. 68.
    Rainsford KD (1999) Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 107(6A):27S–35S; discussion 35S–36SGoogle Scholar
  69. 69.
    Amin AR, Kucuk O, Khuri FR, Shin DM (2009) Perspectives for cancer prevention with natural compounds. J Clin Oncol 27(16):2712–2725. doi:10.1200/JCO.2008.20.6235 PubMedCrossRefGoogle Scholar
  70. 70.
    Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, Tsubono Y, Tsuji I (2006) Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 296(10):1255–1265. doi:10.1001/jama.296.10.1255 PubMedCrossRefGoogle Scholar
  71. 71.
    Koo MW, Cho CH (2004) Pharmacological effects of green tea on the gastrointestinal system. Eur J Pharmacol 500(1–3):177–185. doi:10.1016/j.ejphar.2004.07.023 PubMedCrossRefGoogle Scholar
  72. 72.
    Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, Youdim MB (2005) Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals 14(1–2):46–60. doi:10.1159/000085385 PubMedCrossRefGoogle Scholar
  73. 73.
    Cabrera C, Artacho R, Gimenez R (2006) Beneficial effects of green tea—a review. J Am Coll Nutr 25(2):79–99PubMedCrossRefGoogle Scholar
  74. 74.
    Boehm K, Borrelli F, Ernst E, Habacher G, Hung SK, Milazzo S, Horneber M (2009) Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev (3):CD005004. doi:10.1002/14651858.CD005004.pub2
  75. 75.
    Letter Updating the Green Tea and Risk of Breast Cancer and Prostate cancer Health Claim. (2012). http://www.fda.gov/Food/LabelingNutrition/LabelClaims/QualifiedHealthClaims/ucm301644.htm
  76. 76.
    Connors SK, Chornokur G, Kumar NB (2012) New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer 64(1):4–22. doi:10.1080/01635581.2012.630158 PubMedCrossRefGoogle Scholar
  77. 77.
    Singh BN, Shankar S, Srivastava RK (2011) Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 82(12):1807–1821. doi:10.1016/j.bcp.2011.07.093 PubMedCrossRefGoogle Scholar
  78. 78.
    Lee AH, Fraser ML, Meng X, Binns CW (2006) Protective effects of green tea against prostate cancer. Expert Rev Anticancer Ther 6(4):507–513. doi:10.1586/14737140.6.4.507 PubMedCrossRefGoogle Scholar
  79. 79.
    Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS (2001) Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19(6):1830–1838PubMedGoogle Scholar
  80. 80.
    Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, Dorr RT, Hara Y, Alberts DS (2003) Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 9(9):3312–3319PubMedGoogle Scholar
  81. 81.
    Vincent A, Fitzpatrick LA (2000) Soy isoflavones: are they useful in menopause? Mayo Clin Proc 75(11):1174–1184. doi:10.4065/75.11.1174 PubMedCrossRefGoogle Scholar
  82. 82.
    Pihlajamaa P, Zhang FP, Saarinen L, Mikkonen L, Hautaniemi S, Janne OA (2011) The phytoestrogen genistein is a tissue-specific androgen receptor modulator. Endocrinology 152(11):4395–4405. doi:10.1210/en.2011-0221 PubMedCrossRefGoogle Scholar
  83. 83.
    Horie S (2012) Chemoprevention of prostate cancer: soy isoflavones and curcumin. Korean J Urol 53(10):665–672. doi:10.4111/kju.2012.53.10.665 PubMedCrossRefGoogle Scholar
  84. 84.
    Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J (2007) A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 59(2):163–168. doi:10.1080/01635580701432678 PubMedCrossRefGoogle Scholar
  85. 85.
    Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Besterman-Dahan K, Krischer JP (2010) Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy. J Soc Integr Oncol 8(1):3–13PubMedGoogle Scholar
  86. 86.
    Yan L, Spitznagel EL (2005) Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer 117(4):667–669. doi:10.1002/ijc.21266 PubMedCrossRefGoogle Scholar
  87. 87.
    Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O (2003) Soy isoflavones in the treatment of prostate cancer. Nutr Cancer 47(2):111–117. doi:10.1207/s15327914nc4702_1 PubMedCrossRefGoogle Scholar
  88. 88.
    Ahmad IU, Forman JD, Sarkar FH, Hillman GG, Heath E, Vaishampayan U, Cher ML, Andic F, Rossi PJ, Kucuk O (2010) Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. Nutr Cancer 62(7):996–1000. doi:10.1080/01635581.2010.509839 PubMedCrossRefGoogle Scholar
  89. 89.
    Perabo FG, Von Low EC, Ellinger J, von Rucker A, Muller SC, Bastian PJ (2008) Soy isoflavone genistein in prevention and treatment of prostate cancer. Prostate Cancer Prostatic Dis 11(1):6–12. doi:10.1038/sj.pcan.4501000 PubMedCrossRefGoogle Scholar
  90. 90.
    Mennen LI, Walker R, Bennetau-Pelissero C, Scalbert A (2005) Risks and safety of polyphenol consumption. Am J Clin Nutr 81(1 Suppl):326S–329SPubMedGoogle Scholar
  91. 91.
    Hamilton-Reeves JM, Vazquez G, Duval SJ, Phipps WR, Kurzer MS, Messina MJ (2010) Clinical studies show no effects of soy protein or isoflavones on reproductive hormones in men: results of a meta-analysis. Fertil Steril 94(3):997–1007. doi:10.1016/j.fertnstert.2009.04.038 PubMedCrossRefGoogle Scholar
  92. 92.
    Miltyk W, Craciunescu CN, Fischer L, Jeffcoat RA, Koch MA, Lopaczynski W, Mahoney C, Crowell J, Paglieri J, Zeisel SH (2003) Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am J Clin Nutr 77(4):875–882PubMedGoogle Scholar
  93. 93.
    Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J (2007) Safety of purified isoflavones in men with clinically localized prostate cancer. Nutr Cancer 59(2):169–175. doi:10.1080/01635580701432660 PubMedCrossRefGoogle Scholar
  94. 94.
    Siepmann T, Roofeh J, Kiefer FW, Edelson DG (2011) Hypogonadism and erectile dysfunction associated with soy product consumption. Nutrition 27(7–8):859–862. doi:10.1016/j.nut.2010.10.018 PubMedCrossRefGoogle Scholar
  95. 95.
    Martinez J, Lewi JE (2008) An unusual case of gynecomastia associated with soy product consumption. Endocr Pract 14(4):415–418PubMedCrossRefGoogle Scholar
  96. 96.
    Clinton SK (1998) Lycopene: chemistry, biology, and implications for human health and disease. Nutr Rev 56(2 Pt 1):35–51PubMedGoogle Scholar
  97. 97.
    Ilic D, Forbes KM, Hassed C (2011) Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev (11):CD008007. doi:10.1002/14651858.CD008007.pub2
  98. 98.
    Qualified Health Claims: Letter Regarding Tomatoes and Prostate Cancer (Lycopene Health Claim Coalition) (Docket No. 2004Q-0201) (2004). http://www.fda.gov/Food/LabelingNutrition/LabelClaims/QiualifiedHealthCare/ucm072767.htm
  99. 99.
    Wei MY, Giovannucci EL (2012) Lycopene, tomato products, and prostate cancer incidence: a review and reassessment in the PSA screening era. J Oncol 2012:271063. doi:10.1155/2012/271063 PubMedCrossRefGoogle Scholar
  100. 100.
    Heber D, Lu QY (2002) Overview of mechanisms of action of lycopene. Exp Biol Med (Maywood) 227(10):920–923Google Scholar
  101. 101.
    Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M, Bertram JS, Wood DP Jr (2002) Effects of lycopene supplementation in patients with localized prostate cancer. Exp Biol Med (Maywood) 227(10):881–885Google Scholar
  102. 102.
    Tang L, Jin T, Zeng X, Wang JS (2005) Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in BALB/c nude mice. J Nutr 135(2):287–290PubMedGoogle Scholar
  103. 103.
    Hantz HL, Young LF, Martin KR (2005) Physiologically attainable concentrations of lycopene induce mitochondrial apoptosis in LNCaP human prostate cancer cells. Exp Biol Med (Maywood) 230(3):171–179Google Scholar
  104. 104.
    Ivanov NI, Cowell SP, Brown P, Rennie PS, Guns ES, Cox ME (2007) Lycopene differentially induces quiescence and apoptosis in androgen-responsive and -independent prostate cancer cell lines. Clin Nutr 26(2):252–263. doi:10.1016/j.clnu.2007.01.002 PubMedCrossRefGoogle Scholar
  105. 105.
    Kumar NB, Besterman-Dahan K, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Krischer JP (2008) Results of a randomized clinical trial of the action of several doses of lycopene in localized prostate cancer: administration prior to radical prostatectomy. Clin Med Urol 1:1–14PubMedGoogle Scholar
  106. 106.
    Vogt TM, Mayne ST, Graubard BI, Swanson CA, Sowell AL, Schoenberg JB, Swanson GM, Greenberg RS, Hoover RN, Hayes RB, Ziegler RG (2002) Serum lycopene, other serum carotenoids, and risk of prostate cancer in US Blacks and Whites. Am J Epidemiol 155(11):1023–1032PubMedCrossRefGoogle Scholar
  107. 107.
    van Breemen RB, Sharifi R, Viana M, Pajkovic N, Zhu D, Yuan L, Yang Y, Bowen PE, Stacewicz-Sapuntzakis M (2011) Antioxidant effects of lycopene in African American men with prostate cancer or benign prostate hyperplasia: a randomized, controlled trial. Cancer Prev Res (Phila) 4(5):711–718. doi:10.1158/1940-6207.CAPR-10-0288 CrossRefGoogle Scholar
  108. 108.
    Trumbo PR (2005) Are there adverse effects of lycopene exposure? J Nutr 135(8):2060S–2061SPubMedGoogle Scholar
  109. 109.
    Michael McClain R, Bausch J (2003) Summary of safety studies conducted with synthetic lycopene. Regul Toxicol Pharmacol 37(2):274–285PubMedCrossRefGoogle Scholar
  110. 110.
    De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, Mukhopadhyay AK (2009) Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother 53(4):1592–1597. doi:10.1128/AAC.01242-08 PubMedCrossRefGoogle Scholar
  111. 111.
    Martins CV, da Silva DL, Neres AT, Magalhaes TF, Watanabe GA, Modolo LV, Sabino AA, de Fatima A, de Resende MA (2009) Curcumin as a promising antifungal of clinical interest. J Antimicrob Chemother 63(2):337–339. doi:10.1093/jac/dkn488 PubMedCrossRefGoogle Scholar
  112. 112.
    O’Connell MA, Rushworth SA (2008) Curcumin: potential for hepatic fibrosis therapy? Br J Pharmacol 153(3):403–405. doi:10.1038/sj.bjp.0707580 PubMedCrossRefGoogle Scholar
  113. 113.
    Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL (2005) A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res 2(2):131–136PubMedCrossRefGoogle Scholar
  114. 114.
    Srivastava G, Mehta JL (2009) Currying the heart: curcumin and cardioprotection. J Cardiovasc Pharmacol Ther 14(1):22–27. doi:10.1177/1074248408329608 PubMedCrossRefGoogle Scholar
  115. 115.
    Chainani-Wu N (2003) Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9(1):161–168. doi:10.1089/107555303321223035 PubMedCrossRefGoogle Scholar
  116. 116.
    Bar-Sela G, Epelbaum R, Schaffer M (2010) Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 17(3):190–197PubMedCrossRefGoogle Scholar
  117. 117.
    Aggarwal BB (2008) Prostate cancer and curcumin: add spice to your life. Cancer Biol Ther 7(9):1436–1440PubMedCrossRefGoogle Scholar
  118. 118.
    Hong JH, Ahn KS, Bae E, Jeon SS, Choi HY (2006) The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivo. Prostate Cancer Prostatic Dis 9(2):147–152. doi:10.1038/sj.pcan.4500856 PubMedCrossRefGoogle Scholar
  119. 119.
    Maheshwari RK, Singh AK, Gaddipati J, Srimal RC (2006) Multiple biological activities of curcumin: a short review. Life Sci 78(18):2081–2087. doi:10.1016/j.lfs.2005.12.007 PubMedCrossRefGoogle Scholar
  120. 120.
    Shenouda NS, Zhou C, Browning JD, Ansell PJ, Sakla MS, Lubahn DB, Macdonald RS (2004) Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer 49(2):200–208. doi:10.1207/s15327914nc4902_12 PubMedCrossRefGoogle Scholar
  121. 121.
    Teiten MH, Gaascht F, Eifes S, Dicato M, Diederich M (2010) Chemopreventive potential of curcumin in prostate cancer. Genes Nutr 5(1):61–74. doi:10.1007/s12263-009-0152-3 PubMedCrossRefGoogle Scholar
  122. 122.
    Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG (2011) Safety assessment of a solid lipid curcumin particle preparation: acute and subchronic toxicity studies. Food Chem Toxicol 49(8):1834–1842. doi:10.1016/j.fct.2011.05.001 PubMedCrossRefGoogle Scholar
  123. 123.
    Jiao Y, Jt Wilkinson, Di X, Wang W, Hatcher H, Kock ND, D’Agostino R Jr, Knovich MA, Torti FM, Torti SV (2009) Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 113(2):462–469. doi:10.1182/blood-2008-05-155952 PubMedCrossRefGoogle Scholar
  124. 124.
    Berquin IM, Edwards IJ, Chen YQ (2008) Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 269(2):363–377. doi:10.1016/j.canlet.2008.03.044 PubMedCrossRefGoogle Scholar
  125. 125.
    Friedrichs W, Ruparel SB, Marciniak RA, deGraffenried L (2011) Omega-3 fatty acid inhibition of prostate cancer progression to hormone independence is associated with suppression of mTOR signaling and androgen receptor expression. Nutr Cancer 63(5):771–777. doi:10.1080/01635581.2011.570892 PubMedCrossRefGoogle Scholar
  126. 126.
    Cavazos DA, Price RS, Apte SS, deGraffenried LA (2011) Docosahexaenoic acid selectively induces human prostate cancer cell sensitivity to oxidative stress through modulation of NF-kappaB. Prostate 71(13):1420–1428. doi:10.1002/pros.21359 PubMedCrossRefGoogle Scholar
  127. 127.
    MacLean CH, Newberry SJ, Mojica WA, Khanna P, Issa AM, Suttorp MJ, Lim YW, Traina SB, Hilton L, Garland R, Morton SC (2006) Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA 295(4):403–415. doi:10.1001/jama.295.4.403 PubMedCrossRefGoogle Scholar
  128. 128.
    Sala-Vila A, Calder PC (2011) Update on the relationship of fish intake with prostate, breast, and colorectal cancers. Crit Rev Food Sci Nutr 51(9):855–871. doi:10.1080/10408398.2010.483527 PubMedCrossRefGoogle Scholar
  129. 129.
    Ukoli FA, Fowke JH, Akumabor P, Oguike T, Taher KA, Murff HJ, Amaefuna ER, Kittles R, Ahaghotu C, Osime U, Beech DJ (2010) The association of plasma fatty acids with prostate cancer risk in African Americans and Africans. J Health Care Poor Underserved 21(1 Suppl):127–147. doi:10.1353/hpu.0.0242 PubMedCrossRefGoogle Scholar
  130. 130.
    Williams CD, Whitley BM, Hoyo C, Grant DJ, Iraggi JD, Newman KA, Gerber L, Taylor LA, McKeever MG, Freedland SJ (2011) A high ratio of dietary n-6/n-3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutr Res 31(1):1–8. doi:10.1016/j.nutres.2011.01.002 PubMedCrossRefGoogle Scholar
  131. 131.
    Riediger ND, Othman RA, Suh M, Moghadasian MH (2009) A systemic review of the roles of n-3 fatty acids in health and disease. J Am Diet Assoc 109(4):668–679. doi:10.1016/j.jada.2008.12.022 PubMedCrossRefGoogle Scholar
  132. 132.
    Marik PE, Varon J (2009) Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 32(7):365–372. doi:10.1002/clc.20604 PubMedCrossRefGoogle Scholar
  133. 133.
    Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80(6 Suppl):1678S–1688SPubMedGoogle Scholar
  134. 134.
    Schwartz GG (2009) Vitamin D and intervention trials in prostate cancer: from theory to therapy. Ann Epidemiol 19(2):96–102. doi:10.1016/j.annepidem.2008.03.007 PubMedCrossRefGoogle Scholar
  135. 135.
    Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, Bekkering GE, Fraser WD, Sterne JA, Metcalfe C (2011) Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22(3):319–340. doi:10.1007/s10552-010-9706-3 PubMedCrossRefGoogle Scholar
  136. 136.
    Manson JE, Mayne ST, Clinton SK (2011) Vitamin D and prevention of cancer—ready for prime time? N Engl J Med 364(15):1385–1387. doi:10.1056/NEJMp1102022 PubMedCrossRefGoogle Scholar
  137. 137.
    Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, Chatterjee N, Horst RL, Hollis BW, Huang WY, Shikany JM, Hayes RB (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100(11):796–804. doi:10.1093/jnci/djn152 PubMedCrossRefGoogle Scholar
  138. 138.
    Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN (2010) Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort. Eur J Cancer 46(5):932–936. doi:10.1016/j.ejca.2009.12.030 PubMedCrossRefGoogle Scholar
  139. 139.
    Tseng M, Giri V, Watkins-Bruner D, Giovannucci E (2009) Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer. Cancer Causes Control 20(10):1947–1954. doi:10.1007/s10552-009-9389-9 PubMedCrossRefGoogle Scholar
  140. 140.
    Tseng M, Giri V, Bruner DW, Giovannucci E (2009) Prevalence and correlates of vitamin D status in African American men. BMC Public Health 9:191. doi:10.1186/1471-2458-9-191 PubMedCrossRefGoogle Scholar
  141. 141.
    Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, Horst RL, Ambrose LH, Kindy MS, Gattoni-Celli S (2012) Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab 97(7):2315–2324. doi:10.1210/jc.2012-1451 PubMedCrossRefGoogle Scholar
  142. 142.
    Autier P, Gandini S (2007) Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 167(16):1730–1737PubMedCrossRefGoogle Scholar
  143. 143.
    Halthur C, Johansson AL, Almquist M, Malm J, Gronberg H, Manjer J, Dickman PW (2009) Serum calcium and the risk of prostate cancer. Cancer Causes Control 20(7):1205–1214. doi:10.1007/s10552-009-9342-y PubMedCrossRefGoogle Scholar
  144. 144.
    Williams CD, Whitley BM, Hoyo C, Grant DJ, Schwartz GG, Presti JC Jr, Iraggi JD, Newman KA, Gerber L, Taylor LA, McKeever MG, Freedland SJ (2012) Dietary calcium and risk for prostate cancer: a case-control study among US veterans. Prev Chronic Dis 9:E39PubMedGoogle Scholar
  145. 145.
    Huncharek M, Muscat J, Kupelnick B (2008) Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer 60(4):421–441. doi:10.1080/01635580801911779 PubMedCrossRefGoogle Scholar
  146. 146.
    Rowland GW, Schwartz GG, John EM, Ingles SA (2011) Calcium intake and prostate cancer among African Americans: effect modification by vitamin D receptor calcium absorption genotype. J Bone Miner Res. doi:10.1002/jbmr.505 Google Scholar
  147. 147.
    Mamaeva OA, Kim J, Feng G, McDonald JM (2009) Calcium/calmodulin-dependent kinase II regulates notch-1 signaling in prostate cancer cells. J Cell Biochem 106(1):25–32. doi:10.1002/jcb.21973 PubMedCrossRefGoogle Scholar
  148. 148.
    Sun B, Zhang X, Yonz C, Cummings BS (2010) Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells. Biochem Pharmacol 79(12):1727–1735. doi:10.1016/j.bcp.2010.02.005 PubMedCrossRefGoogle Scholar
  149. 149.
    Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301(1):39–51. doi:10.1001/jama.2008.864 PubMedCrossRefGoogle Scholar
  150. 150.
    Ledesma MC, Jung-Hynes B, Schmit TL, Kumar R, Mukhtar H, Ahmad N (2011) Selenium and vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status. Mol Med 17(1–2):134–143. doi:10.2119/molmed.2010.00136 PubMedGoogle Scholar
  151. 151.
    Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA Jr (2005) Designing the selenium and vitamin E cancer prevention trial (SELECT). J Natl Cancer Inst 97(2):94–102. doi:10.1093/jnci/dji009 PubMedCrossRefGoogle Scholar
  152. 152.
    Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276(24):1957–1963PubMedCrossRefGoogle Scholar
  153. 153.
    Papp LV, Lu J, Holmgren A, Khanna KK (2007) From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal 9(7):775–806. doi:10.1089/ars.2007.1528 PubMedCrossRefGoogle Scholar
  154. 154.
    Hatfield DL, Gladyshev VN (2009) The outcome of selenium and vitamin E cancer prevention trial (SELECT) reveals the need for better understanding of selenium biology. Mol Interv 9(1):18–21. doi:10.1124/mi.9.1.6 PubMedCrossRefGoogle Scholar
  155. 155.
    Klein EA (2009) Selenium and vitamin E: interesting biology and dashed hope. J Natl Cancer Inst 101(5):283–285. doi:10.1093/jnci/djp009 PubMedCrossRefGoogle Scholar
  156. 156.
    Platz EA, Lippman SM (2009) Selenium, genetic variation, and prostate cancer risk: epidemiology reflects back on selenium and vitamin E cancer prevention trial. J Clin Oncol 27(22):3569–3572. doi:10.1200/JCO.2009.22.2117 PubMedCrossRefGoogle Scholar
  157. 157.
    Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK (1998) Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90(6):440–446PubMedCrossRefGoogle Scholar
  158. 158.
    Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S (2002) Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci USA 99(11):7408–7413. doi:10.1073/pnas.102014399 PubMedCrossRefGoogle Scholar
  159. 159.
    Yap WN, Chang PN, Han HY, Lee DT, Ling MT, Wong YC, Yap YL (2008) Gamma-tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signaling pathways. Br J Cancer 99(11):1832–1841. doi:10.1038/sj.bjc.6604763 PubMedCrossRefGoogle Scholar
  160. 160.
    Selenium and Vitamin E Cancer Prevention Trial (SELECT): http://www.cancer.gov/newscenter/qa/2008/selectqa

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  1. 1.Department of Cancer EpidemiologyMoffitt Cancer CenterTampaUSA

Personalised recommendations